Kala Bio enters exclusive US distribution deal with Virotek for ophthalmology genetic testing program
KALA•Profit split and term
Net profit will be split 50-50 once Virotek recoups cost of goods sold; terms are to be reviewed monthly.
The initial term is five years starting Sept. 3, 2026. Kala also receives a right of first refusal on Virotek dispositions of ophthalmological products.
Exclusive U.S. distribution and reseller agreement
Kala Bio entered an exclusive U.S. distribution and reseller agreement with Virotek on Sept. 3, 2026 for an ophthalmology genetic testing program.
Exclusivity hinges on a Sept. 3, 2027 milestone; failure triggers a 30-day cure period, then converts the deal to non-exclusive.
Kala will lead commercialization; Virotek will deliver and administer the program.
